Newbridge Financial Services Group Inc. Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Newbridge Financial Services Group Inc. raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 49.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,076 shares of the company’s stock after acquiring an additional 358 shares during the period. Newbridge Financial Services Group Inc.’s holdings in CRISPR Therapeutics were worth $67,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Itau Unibanco Holding S.A. increased its position in CRISPR Therapeutics by 10.8% in the third quarter. Itau Unibanco Holding S.A. now owns 2,521 shares of the company’s stock worth $114,000 after buying an additional 245 shares in the last quarter. WealthPlan Investment Management LLC boosted its position in shares of CRISPR Therapeutics by 3.1% in the fourth quarter. WealthPlan Investment Management LLC now owns 9,663 shares of the company’s stock worth $605,000 after purchasing an additional 288 shares during the period. Merlin Capital Inc raised its position in shares of CRISPR Therapeutics by 3.3% during the 3rd quarter. Merlin Capital Inc now owns 9,092 shares of the company’s stock valued at $413,000 after purchasing an additional 290 shares during the period. E Fund Management Co. Ltd. increased its stake in CRISPR Therapeutics by 3.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 9,460 shares of the company’s stock worth $592,000 after buying an additional 303 shares in the last quarter. Finally, Corton Capital Inc. lifted its position in shares of CRISPR Therapeutics by 6.1% in the third quarter. Corton Capital Inc. now owns 5,409 shares of the company’s stock valued at $246,000 after acquiring an additional 313 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 0.7 %

Shares of NASDAQ CRSP traded down $0.43 during midday trading on Tuesday, hitting $61.35. The company’s stock had a trading volume of 214,037 shares, compared to its average volume of 1,650,756. The business’s 50 day moving average is $57.06 and its two-hundred day moving average is $65.09. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million during the quarter, compared to analyst estimates of $25.53 million. During the same period last year, the business posted ($0.67) EPS. The company’s revenue was down 99.5% on a year-over-year basis. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -5.51 earnings per share for the current year.

Analyst Ratings Changes

CRSP has been the subject of a number of recent analyst reports. Robert W. Baird upped their price objective on CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, May 9th. TheStreet upgraded shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a research report on Friday, February 23rd. Piper Sandler reissued an “overweight” rating and set a $105.00 price objective on shares of CRISPR Therapeutics in a report on Monday. Finally, Oppenheimer dropped their price target on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus target price of $75.71.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.